Deliver Your News to the World

Smallcapnewsrelease: (OTCBB: OVIT) Oncovista Innovative Therapies, Inc. – Coverage Initiated By Status Equity Research – Long Term Price Target $16.00.


(Smallcapnewsrelease, August 21, 2008) – Jericho, N.Y. – Oncovista Innovative Therapies, Inc. (OTCBB:OVIT) is a biopharmaceutical company engaged in the development and commercialization of targeted cancer therapies and diagnostics.

According to the Status Equity Research report published August 12, 2008, the world market for in vitro diagnostic (IVD) tests for cancer is growing at 11% annually and could reach $8 billion by the end of 2012.

Status concludes that a successful market launch and penetration of OVIT’s AdnaTest, can yield $80 million in first year, post launch sales in the U.S. in 2010. In addition to AdnaTest, OVIT’s novel drug, OVI-237 for the treatment of Metastatic Solid Tumors is scheduled for FDA Phase III registration by the third quarter of 2010.

The research report can be accessed at

Smallcapnewsrelease Best Performing Stocks are Sequenom, Inc. (NASDAQ: SQNM); Genelink, Inc. (NASDAQ: GNLK); Emisphere Technologies, Inc. (NASDAQ: EMIS); Micromet, Inc. (NASDAQ: MITI); Isolagen, Inc. (AMEX: ILE); APP Pharmaceuticals, Inc. (NASDAQ: APPX); Barr Pharmaceuticals, Inc. (NYSE: BRL); Cadence Pharmaceuticals, Inc. (NASDAQ: CADX); and ViroPharma Incorporated (NASDAQ: VPHM)

Smallcapnewsrelease Worst Performing Stocks are Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA); Rexahn Pharmaceuticals, Inc. (AMEX: RNN); Tongjitang Chinese Med Co. (NYSE: TCM); Mdrna, Inc. (NASDAQ: MRNA); Elan Corporation, PLC (NYSE: ELN); Altus Pharmaceuticals, Inc. (NASDAQ: ALTU); Amylin Pharmaceuticals (NASDAQ: AMLN); and Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY).

For more information on Oncovista Innovative Therapies, Inc. visit

For more information on Status Equity visit

Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor’s reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. A third party has hired and paid Smallcapnewsrelease $2,495.00 for the publication of this news release. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. We have no ownership of equity, no representation and do no trading of any kind.


 Cancer Diagnostics
 Pharmaceutical stocks

This news content may be integrated into any legitimate news gathering and publishing effort. Linking is permitted.

News Release Distribution and Press Release Distribution Services Provided by WebWire.